FOLD Amicus Therapeutics, Inc. Stock Quote

FOLD [NASD]

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	0.80%	Shs Outstand	267.46M	Perf Week	-5.54%
Market Cap	2.48B	Forward P/E	-	EPS next Y	-0.35	Insider Trans	-12.67%	Shs Float	250.39M	Perf Month	-26.58%
Income	-238.60M	PEG	-	EPS next Q	-0.15	Inst Own	-	Short Float	10.41%	Perf Quarter	-14.37%
Sales	293.90M	P/S	8.45	EPS this Y	27.90%	Inst Trans	-0.01%	Short Ratio	10.14	Perf Half Y	-6.75%
Book/sh	1.41	P/B	6.17	EPS next Y	64.90%	ROA	-27.70%	Target Price	17.33	Perf Year	-54.92%
Cash/sh	1.95	P/C	4.46	EPS next 5Y	-	ROE	-84.60%	52W Range	8.40 - 21.07	Perf YTD	-24.68%
Dividend	-	P/FCF	-	EPS past 5Y	2.30%	ROI	-38.00%	52W High	-58.71%	Beta	1.29
Dividend %	-	Quick Ratio	5.20	Sales past 5Y	-	Gross Margin	87.70%	52W Low	3.51%	ATR	0.77
Employees	483	Current Ratio	5.40	Sales Q/Q	18.00%	Oper. Margin	-67.80%	RSI (14)	35.72	Volatility	8.07% 8.03%
Optionable	Yes	Debt/Eq	1.03	EPS Q/Q	23.90%	Profit Margin	-81.20%	Rel Volume	0.95	Prev Close	9.19
Shortable	Yes	LT Debt/Eq	1.03	Earnings	Nov 09 BMO	Payout	-	Avg Volume	2.57M	Price	8.70
Recom	2.10	SMA20	-17.26%	SMA50	-19.98%	SMA200	-16.43%	Volume	2,435,915	Change	-5.33%

Jan-14-22

Upgrade

SVB Leerink

Mkt Perform → Outperform

$12 → $16

Nov-15-21

Upgrade

Stifel

Hold → Buy

$12 → $16

Sep-30-21

Upgrade

JP Morgan

Neutral → Overweight

$16

Jul-19-21

Resumed

BTIG Research

Buy

$15

May-27-21

Initiated

Needham

Hold

May-21-21

Initiated

UBS

Buy

$16

Apr-14-21

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$17

Mar-02-21

Initiated

Stifel

Hold

$13

Feb-12-21

Downgrade

JP Morgan

Overweight → Neutral

$19

Feb-12-21

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$30 → $17

Dec-28-20

Resumed

Cantor Fitzgerald

Overweight

$20 → $30

Dec-10-20

Downgrade

Citigroup

Buy → Neutral

$20 → $27

Nov-11-20

Initiated

Berenberg

Hold

Jun-17-20

Initiated

BTIG Research

Buy

$19

Feb-04-20

Resumed

Cantor Fitzgerald

Overweight

$19 → $20

Nov-12-19

Reiterated

H.C. Wainwright

Buy

$18 → $20

Jun-17-19

Initiated

H.C. Wainwright

Buy

$18

Jun-05-19

Reiterated

Cantor Fitzgerald

Overweight

$20 → $19

Apr-05-19

Initiated

Janney

Buy

Jan-30-19

Initiated

Cantor Fitzgerald

Overweight

$20

Jan-13-22 02:26AM	Amicus Therapeutics (FOLD) Stock Jumps 6.4%: Will It Continue to Soar? Zacks
Jan-10-22 07:00AM	Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance GlobeNewswire -17.18%
Jan-05-22 07:00AM	Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-26-21 07:46AM	Is Amicus Therapeutics (NASDAQ:FOLD) Using Too Much Debt? Simply Wall St.
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com -5.16%
Dec-10-21 12:10PM	Hedge Funds Are Selling Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-06-21 11:51AM	Amicus (FOLD) Filings for AT-GAA in Pompe Disease Accepted by EMA Zacks
Dec-03-21 07:00AM	European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease GlobeNewswire -6.11%
Nov-24-21 07:00AM	Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference GlobeNewswire
Nov-22-21 07:00AM	Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism GlobeNewswire
Nov-18-21 07:00AM	The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease GlobeNewswire
Nov-11-21 07:00AM	Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference GlobeNewswire
06:42AM	Amicus Therapeutics, Inc.'s stock is down 7.1%, but insiders still have about US$78k in profit after buying earlier this year Simply Wall St.
Nov-10-21 10:42AM	Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss Zacks
Nov-09-21 04:00PM	Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript Motley Fool -5.11%
08:25AM	Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates GlobeNewswire
Nov-04-21 11:16AM	Notable Amicus Therapeutics Insider Trades $520K In Company Stock Benzinga
Nov-03-21 09:20AM	Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss Zacks
07:00AM	Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021 GlobeNewswire
Oct-28-21 03:06PM	Will Amicus Therapeutics (FOLD) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-27-21 10:02AM	Can Amicus Therapeutics (FOLD) Climb 77% to Reach the Level Wall Street Analysts Expect? Zacks
Oct-26-21 12:05PM	Should I Buy First Bancorp (FBP)? Insider Monkey
Oct-23-21 06:08AM	15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors Insider Monkey
01:04AM	Lifshitz Law Firm, P.C. Announces Investigation of FOLD, BCML, FIBK, and TGP ACCESSWIRE
Oct-19-21 02:00PM	MERGER ALERT DUNE, and FOLD: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies ACCESSWIRE
10:57AM	Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal Zacks
Oct-15-21 08:49AM	10 Best Biotech Stocks to Buy According to Joseph Edelmans Perceptive Advisors Insider Monkey
Oct-12-21 05:36AM	Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy? Insider Monkey
Oct-11-21 10:24AM	Wall Street Analysts Predict a 59% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know Zacks
Oct-05-21 12:17PM	Notable Amicus Therapeutics Insider Trades $150K In Company Stock Benzinga
Oct-04-21 05:44PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Amicus Therapeutics, Inc. with ARYA Sciences Acquisition Corp IV Newsfile
Sep-30-21 12:26PM	Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA Zacks
08:18AM	Amicus stock is up 5%, the day after announcing plans to sell its gene therapy business MarketWatch
06:24AM	Amicus Therapeutics Stock Rises; Sells Unit Stake in SPAC Deal TheStreet.com
Sep-29-21 05:30PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD) ACCESSWIRE -5.11%
03:02PM	Amicus Therapeutics spins off genetic medicine unit in $600M SPAC deal American City Business Journals
08:13AM	The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga
06:30AM	U.S. FDA Accepts Filings for Amicus AT-GAA for the Treatment of Pompe Disease GlobeNewswire
06:30AM	Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: Caritas Therapeutics GlobeNewswire
Sep-20-21 07:00AM	Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society GlobeNewswire
Sep-16-21 08:12AM	Those who invested in Amicus Therapeutics (NASDAQ:FOLD) five years ago are up 43% Simply Wall St.
Sep-03-21 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021 GlobeNewswire
Aug-09-21 12:43PM	Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval Zacks
Aug-06-21 12:24PM	Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up Zacks
Aug-05-21 07:00PM	Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript Motley Fool
08:35AM	Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates GlobeNewswire
Aug-04-21 07:00AM	Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference GlobeNewswire
Aug-02-21 07:00AM	Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease GlobeNewswire
Jul-29-21 03:05PM	Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-27-21 07:00AM	Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021 GlobeNewswire
Jul-06-21 10:06AM	Here is What Hedge Funds Think About Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Jun-22-21 07:21AM	Intuit Launches New Accelerator for AI-focused Startups to Help Communities Overcome Financial Challenges in North America Business Wire
06:00AM	America's SBDC Collaborates with Coalition of Small Business Providers for "Launchpad America" to Help Entrepreneurs, Startups Succeed as Nation Emerges from Pandemic PR Newswire
Jun-14-21 07:00AM	Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors GlobeNewswire
Jun-09-21 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report? Zacks
Jun-08-21 07:00AM	Amicus Therapeutics Announces United Kingdoms MHRA Grants Early Access to AT-GAA GlobeNewswire
Jun-03-21 06:48AM	Increases to Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Compensation Might Cool off for now Simply Wall St.
May-29-21 04:00AM	Insider Buying: The Amicus Therapeutics, Inc. (NASDAQ:FOLD) Independent Director Just Bought 274% More Shares Simply Wall St.
May-28-21 07:00AM	Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference GlobeNewswire
May-21-21 07:00AM	Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases GlobeNewswire
May-11-21 11:55AM	Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y Zacks
May-10-21 06:30PM	Amicus Therapeutics Inc (FOLD) Q1 2021 Earnings Call Transcript Motley Fool
09:05AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates GlobeNewswire
06:45AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-07-21 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021 GlobeNewswire
May-06-21 07:00AM	Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development GlobeNewswire
May-05-21 01:21PM	Is Amicus Therapeutics Inc. (FOLD) A Smart Long-Term Buy? Insider Monkey
07:00AM	Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting GlobeNewswire
May-03-21 03:01PM	Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
08:30AM	Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease Benzinga
07:00AM	Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease GlobeNewswire
Apr-28-21 07:00AM	Amicus Therapeutics Recognized as a Great Place to Work® in Europe GlobeNewswire
Apr-26-21 07:00AM	Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021 GlobeNewswire
Apr-18-21 05:40AM	Is Amicus Therapeutics (NASDAQ:FOLD) Using Debt Sensibly? Simply Wall St.
Apr-14-21 12:33PM	Why Amicus Therapeutics Stock Is Soaring Today Motley Fool +7.20%
Apr-08-21 10:47AM	Is FOLD Stock A Buy or Sell? Insider Monkey
Mar-15-21 07:00AM	Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference GlobeNewswire
Mar-02-21 12:51PM	Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold Zacks -5.26%
01:30AM	Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript Motley Fool
Mar-01-21 08:35AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:24AM	Amicus Therapeutics: Q4 Earnings Insights Benzinga
07:00AM	Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates GlobeNewswire
06:30AM	Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-21 10:10AM	Earnings Preview for Amicus Therapeutics Benzinga
Feb-18-21 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-17-21 07:00AM	Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021 GlobeNewswire
Feb-12-21 04:22PM	Why This Rare-Disease Biotech Stock Just Lost A Third Of Its Value Investor's Business Daily -32.89%
10:06AM	Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021 Benzinga
07:55AM	SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out MarketWatch
07:19AM	Amicus Reports Disappointing Tests Results for Pompe Disease Drug TheStreet.com
Feb-11-21 04:01PM	Amicus AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study GlobeNewswire
Feb-08-21 02:30PM	Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium 2021 GlobeNewswire
02:30PM	Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium 2021 GlobeNewswire
Jan-28-21 08:40AM	Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options Zacks

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crowley John F	Chairman & CEO	Jan 18	Sale	10.23	8,564	87,610	976,435	Jan 19 06:43 PM
Crowley John F	Chairman & CEO	Jan 05	Sale	12.18	63,543	774,119	655,131	Jan 07 05:20 PM
Campbell Bradley L	Chief Operating Officer	Jan 03	Option Exercise	3.53	5,470	19,309	412,211	Jan 04 08:58 PM
Campbell Bradley L	Chief Operating Officer	Jan 03	Sale	11.86	5,470	64,880	406,741	Jan 04 08:58 PM
Campbell Bradley L	Chief Operating Officer	Dec 22	Option Exercise	4.38	3,000	13,140	460,268	Dec 23 04:14 PM
Campbell Bradley L	Chief Operating Officer	Dec 22	Sale	11.70	3,000	35,096	457,268	Dec 23 04:14 PM
Campbell Bradley L	Chief Operating Officer	Dec 01	Option Exercise	4.38	10,515	46,056	467,783	Dec 02 08:42 PM
Campbell Bradley L	Chief Operating Officer	Dec 01	Sale	11.00	10,515	115,706	457,268	Dec 02 08:42 PM
Crowley John F	Chairman & CEO	Nov 15	Option Exercise	4.38	24,935	109,215	849,461	Nov 17 07:30 PM
Crowley John F	Chairman & CEO	Nov 15	Sale	11.75	24,935	292,951	824,526	Nov 17 07:30 PM
Crowley John F	Chairman & CEO	Nov 03	Option Exercise	3.82	27,739	105,963	852,265	Nov 03 06:30 PM
Crowley John F	Chairman & CEO	Nov 03	Sale	12.00	27,739	332,868	824,526	Nov 03 06:30 PM
Campbell Bradley L	Chief Operating Officer	Nov 01	Option Exercise	4.38	10,515	46,056	467,783	Nov 03 06:29 PM
WHITMAN BURKE W	Director	Nov 01	Buy	10.49	1,500	15,735	65,082	Nov 03 06:31 PM
Crowley John F	Chairman & CEO	Nov 01	Sale	10.80	7,819	84,451	824,526	Nov 03 06:30 PM
Campbell Bradley L	Chief Operating Officer	Nov 01	Sale	11.32	10,515	119,054	457,268	Nov 03 06:29 PM
Crowley John F	Chairman & CEO	Oct 15	Option Exercise	4.38	22,000	96,360	854,345	Oct 18 09:42 PM
Crowley John F	Chairman & CEO	Oct 15	Sale	11.22	22,000	246,871	832,345	Oct 18 09:42 PM
Campbell Bradley L	Chief Operating Officer	Oct 01	Option Exercise	4.38	10,515	46,056	467,783	Oct 04 06:58 PM
WHITMAN BURKE W	Director	Oct 01	Buy	9.56	1,500	14,346	63,582	Oct 04 07:00 PM
Crowley John F	Chairman & CEO	Oct 01	Sale	10.00	7,500	75,000	832,345	Oct 04 06:59 PM
Campbell Bradley L	Chief Operating Officer	Oct 01	Sale	10.00	10,515	105,150	457,268	Oct 04 06:58 PM
Crowley John F	Chairman & CEO	Sep 15	Option Exercise	4.38	22,000	96,360	861,845	Sep 17 05:27 PM
Crowley John F	Chairman & CEO	Sep 15	Sale	11.08	22,000	243,828	839,845	Sep 17 05:27 PM
Prout Samantha	Principal Accounting Officer	Sep 03	Option Exercise	9.75	4,925	48,004	88,095	Sep 08 06:42 PM
Crowley John F	Chairman & CEO	Sep 03	Option Exercise	3.73	5,238	19,563	845,083	Sep 08 06:45 PM
Crowley John F	Chairman & CEO	Sep 03	Sale	12.02	5,238	62,944	839,845	Sep 08 06:45 PM
Prout Samantha	Principal Accounting Officer	Sep 03	Sale	12.01	4,925	59,168	83,170	Sep 08 06:42 PM
Campbell Bradley L	Chief Operating Officer	Sep 01	Option Exercise	4.38	10,515	46,056	467,783	Sep 07 06:56 PM
WHITMAN BURKE W	Director	Sep 01	Buy	11.41	1,500	17,115	62,082	Sep 07 06:53 PM
Campbell Bradley L	Chief Operating Officer	Sep 01	Sale	11.50	10,515	120,905	457,268	Sep 07 06:56 PM
Crowley John F	Chairman & CEO	Sep 01	Sale	11.50	7,500	86,250	839,845	Sep 07 06:55 PM
Prout Samantha	Principal Accounting Officer	Aug 23	Sale	11.00	5,045	55,495	83,170	Aug 25 05:55 PM
Crowley John F	Chairman & CEO	Aug 16	Option Exercise	4.38	22,000	96,360	869,345	Aug 18 06:36 PM
Crowley John F	Chairman & CEO	Aug 16	Sale	10.27	22,000	225,918	847,345	Aug 18 06:36 PM
Campbell Bradley L	Chief Operating Officer	Aug 05	Option Exercise	4.38	21,028	92,103	478,296	Aug 09 08:19 PM
Crowley John F	Chairman & CEO	Aug 05	Option Exercise	4.38	22,000	96,360	884,345	Aug 09 08:21 PM
Crowley John F	Chairman & CEO	Aug 05	Sale	10.03	37,000	371,047	847,345	Aug 09 08:21 PM
Campbell Bradley L	Chief Operating Officer	Aug 05	Sale	10.02	21,028	210,671	457,268	Aug 09 08:19 PM
WHITMAN BURKE W	Director	Aug 02	Buy	9.28	1,500	13,920	60,582	Aug 04 05:12 PM
Crowley John F	Chairman & CEO	Jul 12	Sale	9.31	14,885	138,652	862,345	Jul 14 09:08 PM
WHITMAN BURKE W	Director	Jul 01	Buy	9.60	1,500	14,400	59,082	Jul 14 09:09 PM
Crowley John F	Chairman & CEO	Jun 15	Option Exercise	4.38	22,000	96,360	899,230	Jun 17 08:06 PM
Crowley John F	Chairman & CEO	Jun 15	Sale	10.26	22,000	225,632	877,230	Jun 17 08:06 PM
Campbell Bradley L	Chief Operating Officer	Jun 07	Option Exercise	3.21	73,110	234,659	474,618	Jun 09 07:30 PM
Crowley John F	Chairman & CEO	Jun 07	Option Exercise	6.31	22,000	138,913	906,730	Jun 09 07:31 PM
Crowley John F	Chairman & CEO	Jun 07	Sale	10.01	29,500	295,192	877,230	Jun 09 07:31 PM
Campbell Bradley L	Chief Operating Officer	Jun 07	Sale	10.01	10,514	105,207	457,268	Jun 09 07:30 PM
WHITMAN BURKE W	Director	Jun 01	Buy	9.24	1,500	13,861	47,467	Jun 02 06:26 PM
Bleil Lynn Dorsey	Director	May 25	Buy	8.74	28,605	250,008	50,310	May 27 04:16 PM
RAAB MICHAEL	Director	May 18	Option Exercise	7.56	5,634	42,593	26,634	May 20 05:03 PM
Campbell Bradley L	Chief Operating Officer	May 03	Option Exercise	6.45	10,514	67,815	422,536	May 05 05:59 PM
MCGLYNN MARGARET G	Director	May 03	Option Exercise	7.51	10,000	75,100	37,919	May 05 06:01 PM
WHITMAN BURKE W	Director	May 03	Buy	10.21	1,500	15,315	45,967	May 05 06:00 PM
MCGLYNN MARGARET G	Director	May 03	Sale	10.27	10,000	102,704	27,919	May 05 06:01 PM
Crowley John F	Chairman & CEO	May 03	Sale	10.28	7,500	77,089	884,730	May 05 05:59 PM
Campbell Bradley L	Chief Operating Officer	May 03	Sale	10.27	10,514	107,970	412,022	May 05 05:59 PM
Crowley John F	Chairman & CEO	Apr 22	Sale	10.01	7,683	76,898	892,230	Apr 26 05:37 PM
Crowley John F	Chairman & CEO	Apr 15	Option Exercise	6.45	22,000	141,900	921,913	Apr 19 07:21 PM
Crowley John F	Chairman & CEO	Apr 15	Sale	10.09	22,000	222,086	899,913	Apr 19 07:21 PM
Campbell Bradley L	Chief Operating Officer	Apr 01	Option Exercise	6.45	10,514	67,815	389,371	Apr 05 06:19 PM
WHITMAN BURKE W	Director	Apr 01	Buy	10.00	1,500	15,000	44,467	Apr 05 06:15 PM
Campbell Bradley L	Chief Operating Officer	Apr 01	Sale	10.03	10,514	105,505	378,857	Apr 05 06:19 PM
Crowley John F	Chairman & CEO	Apr 01	Sale	10.00	7,500	75,000	821,524	Apr 05 06:17 PM
Crowley John F	Chairman & CEO	Mar 22	Sale	10.29	7,682	79,061	829,024	Mar 24 05:11 PM
Crowley John F	Chairman & CEO	Mar 15	Option Exercise	6.45	22,000	141,900	858,706	Mar 17 07:11 PM
Crowley John F	Chairman & CEO	Mar 15	Sale	10.77	22,000	236,988	836,706	Mar 17 07:11 PM
Quimi Daphne	Chief Financial Officer	Mar 05	Option Exercise	2.94	16,628	48,886	275,998	Mar 09 05:38 PM
Campbell Bradley L	Chief Operating Officer	Mar 01	Option Exercise	6.45	10,514	67,815	389,371	Mar 03 07:03 PM
WHITMAN BURKE W	Director	Mar 01	Buy	12.40	1,500	18,600	42,967	Mar 03 06:58 PM
Crowley John F	Chairman & CEO	Mar 01	Sale	11.85	7,500	88,881	836,706	Mar 03 07:04 PM
Campbell Bradley L	Chief Operating Officer	Mar 01	Sale	11.84	10,514	124,516	378,857	Mar 03 07:03 PM
Crowley John F	Chairman & CEO	Feb 22	Sale	11.98	7,682	92,027	844,206	Feb 24 05:07 PM
Crowley John F	Chairman & CEO	Feb 16	Option Exercise	6.45	22,000	141,900	873,888	Feb 18 06:48 PM
Crowley John F	Chairman & CEO	Feb 16	Sale	12.26	22,000	269,700	851,888	Feb 18 06:48 PM
Campbell Bradley L	Chief Operating Officer	Feb 01	Option Exercise	6.45	10,514	67,815	389,371	Feb 03 05:58 PM
WHITMAN BURKE W	Director	Feb 01	Buy	19.09	1,500	28,637	41,467	Feb 03 06:00 PM
Crowley John F	Chairman & CEO	Feb 01	Sale	19.08	7,500	143,077	851,888	Feb 03 05:59 PM
Campbell Bradley L	Chief Operating Officer	Feb 01	Sale	19.08	10,514	200,571	378,857	Feb 03 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience